Albiglutide

In plain language

Albiglutide was a once-weekly injection for type 2 diabetes in the GLP-1 family, sold as Tanzeum in the U.S. and Eperzan in Europe. It is no longer sold anywhere.

Instead of adding a fatty acid tag, its makers fused two copies of a GLP-1-like peptide directly to human blood albumin, one of the most common proteins in the body. This made it last a week but also made it bulky, which weakened how strongly it could switch on its receptor.

For students

Albiglutide is a fusion protein (about 72 kDa) containing two tandem copies of a modified GLP-1 (DPP-4-resistant) sequence fused to human serum albumin via a glycine linker. Albumin fusion extends half-life to about 5 days, allowing once-weekly dosing.

Approved by the FDA in 2014 for type 2 diabetes, it was voluntarily withdrawn worldwide by GSK in 2017-2018 for commercial reasons, not safety. Notably, its cardiovascular outcomes trial, HARMONY Outcomes, completed after the withdrawal decision and showed a significant reduction in major adverse cardiovascular events, evidence that arrived too late to change the product's commercial fate.

For researchers and instructors

Biochemistry. Dimeric GLP-1 mimic design reduces potency per molecule (larger, less flexible ligand), offset by long exposure; DPP-4-resistant via alanine-to-alanine substitutions at position 8 of each repeat.

Pharmacology. Once-weekly 30/50 mg subcutaneous dosing, albumin-mediated distribution; HbA1c lowering modest relative to later agonists.

Human evidence. HARMONY program Phase 3 trials for efficacy; HARMONY Outcomes (9,461 patients) showed 22% relative reduction in MACE, published in The Lancet in 2018.

Teaching point. A business-withdrawal case whose outcomes trial succeeded post-mortem, a now-standard citation in drug development and commercialization teaching.